Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript

Group 1 - The company aims to develop a platform to isolate and quantify the activity of live patient tumor cells to identify patients responsive to targeted therapies [1] - The company has been working in the PI3K space and has identified gedatolisib, a pan-PI3K/mTOR inhibitor, which began development in 2021 [2] - The company has completed one Phase III study and is preparing to report another in the second-line setting for breast cancer, along with a first-line study and an early phase study in prostate cancer [2]